Nucala is a medicine for severe asthma and some other conditions caused by too many eosinophils, a type of white blood cell. It is given as a shot under the skin, usually once a month. It works by blocking a signal the body uses to make these cells, which lowers swelling.
Every report comes from a Lived member, sent anonymously.
Have you tried Nucala (Mepolizumab) for Asthma?
Mepolizumab, sold as Nucala, is a prescription injection for diseases driven by eosinophils, a type of white blood cell that can build up and cause ongoing inflammation. It is a biologic medicine, meaning a lab-made antibody rather than a conventional pill or inhaler. Its most common use is severe asthma with an eosinophilic pattern (usually shown by a raised eosinophil count on a blood test) in adults and children aged 6 and older. It is also approved for adults with chronic sinus inflammation and nasal polyps that nasal steroid sprays have not controlled, and for adults with COPD (chronic obstructive pulmonary disease) whose flare-ups continue despite inhalers and who also have raised eosinophils. For asthma, nasal polyps and COPD, it is an add-on: people keep their usual maintenance treatment and Nucala is given alongside it. Nucala also treats two rarer conditions: eosinophilic granulomatosis with polyangiitis (EGPA), an inflammation of small blood vessels that usually occurs with asthma, in adults; and hypereosinophilic syndrome (HES), in which very high eosinophil levels can damage organs, in people aged 12 and older who have had it for at least six months without another identifiable cause.
Eosinophils depend on a signaling protein called interleukin-5 (IL-5) to grow, mature, move into tissues and survive. In eosinophilic asthma and related conditions, these cells gather in the airways, sinuses or blood vessels and contribute to swelling, mucus and tissue damage. Mepolizumab is an antibody that attaches to IL-5 and stops it from reaching eosinophils. With less IL-5 signaling, the body makes fewer eosinophils and they survive for a shorter time, so blood eosinophil counts fall within days of a dose. Inflammation in these diseases involves many cell types, though, and lowering eosinophils does not fully explain why some people improve a great deal and others only a little.
Nucala is injected under the skin of the thigh, abdomen or upper arm once every 4 weeks. The usual dose for asthma in people 12 and older, nasal polyps and COPD is 100 mg. Children aged 6 to 11 with severe asthma get a smaller 40 mg dose from a dedicated syringe, given by a health professional or caregiver. For EGPA and HES, the dose is 300 mg, given as three separate 100 mg injections at least 2 inches apart at the same visit. Some people receive every dose in a clinic, where the powdered form is mixed and injected by staff. Others, aged 12 and older, are trained to use a prefilled pen or syringe at home once their clinician decides that is appropriate. The pens and syringes are kept in the refrigerator and left at room temperature for about 30 minutes before injecting. If a dose is missed, it is given as soon as possible and then the usual schedule resumes.
In asthma studies, headache, back pain, tiredness and reactions where the needle went in (pain, redness, swelling or itching) were the most commonly reported problems. People with nasal polyps more often noticed a sore throat and joint pain, and people with COPD back pain, diarrhea and cough. These effects were usually mild, and several occurred nearly as often with placebo injections. Allergic reactions are uncommon but can be serious. They usually appear within hours of an injection but can start days later. Hives, rash or flushing after a dose should be reported to the care team promptly, and Nucala is usually stopped if a true allergic reaction occurs. Swelling of the face, lips or tongue, trouble breathing or swallowing, or dizziness or fainting after a dose needs emergency medical care.
Nucala does not work as a rescue medicine. It will not stop an asthma attack or an acute COPD flare that is already happening, so people should keep using their quick-relief inhaler and their action plan as before. People who take steroid tablets or inhaled steroids should not stop or suddenly reduce them because they have started Nucala. Lowering steroids is often a goal, but it is done gradually under a doctor's supervision, because quick reductions can cause withdrawal symptoms or let conditions that the steroids were controlling come back. Shingles (herpes zoster) has occurred in people taking Nucala, so it is reasonable to ask whether the shingles vaccine makes sense before or during treatment. Because eosinophils help the body fight some parasitic worm infections, a known worm infection should be treated before starting. No formal drug interaction studies have been done. There is too little information to know whether Nucala affects a developing baby. Antibodies like this one cross the placenta more in later pregnancy, but poorly controlled asthma also carries real risks for pregnancy, so anyone pregnant, planning pregnancy or breastfeeding should weigh the options with their specialist rather than stopping on their own.
Blood eosinophils drop quickly, but the benefit people care about, fewer flare-ups, is judged over months rather than after one or two injections. In severe eosinophilic asthma, medicines in this group roughly halve the number of serious flare-ups that need steroid tablets, and Nucala helped some people who depend on daily steroid tablets reduce their dose while keeping asthma under control. Changes in breathing test results and day-to-day symptom scores tend to be smaller, and some people notice little difference. In other conditions, the benefits are measured differently. In a year-long nasal polyp study, 9% of people taking Nucala needed polyp surgery compared with 23% of those on placebo, and nasal blockage and sense of smell improved. In COPD with raised eosinophils, flare-ups were about 20% less frequent. In EGPA and HES, more people stayed in remission or avoided flares. The care team usually reviews progress by counting flare-ups, steroid courses and symptoms against the period before treatment. If asthma or COPD stays poorly controlled or gets worse after starting, the team should hear about it, since another biologic or a different approach may suit better. Nucala is a maintenance treatment, so when it helps it is normally continued as part of the regular plan rather than used in short courses.
Last reviewed • Oct 2026
Educational content, not medical advice.
Share your experience taking Nucala (Mepolizumab), what you've noticed, or ask the community a question.